GSK to Acquire IDRx for $1.15 Billion in Strategic Expansion
London: British drug maker GSK announced its plan to acquire the US biopharmaceutical company IDRx for up to $1.15 billion. The acquisition is aimed at enhancing GSK’s portfolio in the field of oncology, particularly focusing on gastrointestinal strom…